Registration Statement Related To Cleveland BioLabs-Cytocom Merger Declared Effective By SEC

• Cleveland BioLabs Inc (NASDAQ: CBLI) says that the SEC registration statement regarding the previously announced merger with Cytocom Inc was declared effective by the SEC on June 10.

• The merger is expected to close in the Q3 of 2021, subject to approval by Cleveland BioLabs' stockholders.

• A special meeting of the Cleveland BioLabs stockholders related to the merger will be held virtually on July 6 at 10:00 a.m. E.T.

• After the deal's closure, the new combined company will be named Cytocom Inc, and its common stock will trade on NASDAQ under the symbol "CYTO."

• The deal was initially announced in October last year, and the registration document was filed in February.

• Price Action: CBLI shares are up 8.66% at $5.27 during the premarket trading session on the last check Friday.

See more from Benzinga

• Click here for options trades from Benzinga

• Codexis Raises 2021 Revenue Outlook After New Order For Its Enzyme Product

• BioNTech Starts Dosing In Mid-Stage Melanoma Vaccine Trial

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.